# Alerus Financial Corp: overview

ALRS · Nasdaq · CIK 903419 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alrs.md) · [Financials](/companies/alrs/financials.md) · [Filings](/companies/alrs/filings.md) · [Insiders](/companies/alrs/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [0.26](/filings/0001437749-25-033350.md) | not reported | [0.52](/filings/0001437749-26-014481.md) | [0.78](/filings/0001437749-26-025463.md) | [0.65](/filings/0001437749-25-033350.md) | not reported | [0.89](/filings/0001437749-26-014481.md) | [0.81](/filings/0001437749-26-025463.md) |
| Free cash flow | $m | [17.4 d](/filings/0001437749-25-033350.md) | [(2.7) d](/filings/0001437749-26-006820.md) | [5.7](/filings/0001437749-26-014481.md) | [7.6 d](/filings/0001437749-26-025463.md) | [30.3 d](/filings/0001437749-25-033350.md) | [15.3 d](/filings/0001437749-26-006820.md) | [25.8](/filings/0001437749-26-014481.md) | [17.9 d](/filings/0001437749-26-025463.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL not reported.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [2.97](/filings/0001558370-24-002829.md) | [2.10](/filings/0001437749-25-007629.md) | [0.58](/filings/0001437749-26-006820.md) | [0.83](/filings/0001437749-26-006820.md) | [0.68](/filings/0001437749-26-006820.md) |
| Free cash flow | $m | [148](/filings/0001558370-24-002829.md) | [101](/filings/0001437749-25-007629.md) | [23.7](/filings/0001437749-26-006820.md) | [9.4](/filings/0001437749-26-006820.md) | [58.8](/filings/0001437749-26-006820.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL not reported.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/alrs/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [ALERUS FINANCIAL NA](/funds/919458.md) | 2026-06-30 | $65.8m | 2,116,173 |  | Reduced −125,568 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $56.7m | 1,822,242 |  | Added +61,491 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $29.4m | 945,852 |  | Reduced −15,924 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $29.3m | 943,445 |  | Added +56,630 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $20.4m | 655,184 |  | Added +37,508 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $17.6m | 561,249 |  | Added +68,087 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $16.3m | 525,321 |  | Added +158,794 |
| [Stieven Capital Advisors, L.P.](/funds/1388279.md) | 2026-06-30 | $11.9m | 382,034 |  | Added +43,110 |
| [Phocas Financial Corp.](/funds/1356783.md) | 2026-06-30 | $11.0m | 354,155 |  | Added +93,259 |
| [BANC FUNDS CO LLC](/funds/1029311.md) | 2026-06-30 | $10.9m | 349,165 |  | Unchanged |

## Recent filings

[All 422 filings](/companies/alrs/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-27 | 20:02 ET | [8-K](/filings/0001437749-26-029099.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-029099 |
| 2026-08-03 | 20:43 ET | [10-Q](/filings/0001437749-26-025463.md) | Quarterly report, period 2026-06-30 | 0001437749-26-025463 |
| 2026-07-29 | 20:31 ET | [8-K](/filings/0001437749-26-024891.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-024891 |
| 2026-05-22 | 20:31 ET | [8-K](/filings/0001437749-26-018262.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-018262 |
| 2026-05-19 | 18:46 ET | [8-K](/filings/0001437749-26-017761.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-017761 |
| 2026-05-15 | 20:02 ET | [8-K](/filings/0001437749-26-017369.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-26-017369 |
| 2026-05-01 | 20:32 ET | [10-Q](/filings/0001437749-26-014481.md) | Quarterly report, period 2026-03-31 | 0001437749-26-014481 |
| 2026-04-29 | 20:30 ET | [8-K](/filings/0001437749-26-013893.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-013893 |
| 2026-04-01 | 20:15 ET | [DEF 14A](/filings/0001437749-26-010883.md) | Proxy statement, period 2026-05-14 | 0001437749-26-010883 |
| 2026-03-31 | 20:06 ET | [8-K](/filings/0001437749-26-010637.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001437749-26-010637 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-006820.md), filed Mar 4, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 903419
- Tickers: ALRS
- Exchange: Nasdaq
- SIC code: 6021 National Commercial Banks
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.